Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Study shows vitamin C can facilitate the generation of embryonic stem cells from adult cells

Famous for its antioxidant properties and role in tissue repair, vitamin C is touted as beneficial for illnesses ranging from the common cold to cancer and perhaps even for slowing the aging process. Now, a study published online on December 24th by Cell Press in the journal Cell Stem Cell uncovers an unexpected new role for this natural compound: facilitating the generation of embryonic-like stem cells from adult cells.

28 Dec 2009

RP International benefit "The Eyes of Christmas" to be telecast to 160 million homes

The 15th annual "Eyes of Christmas" presentation is being telecast over multiple broadcasts, cable and satellite networks, as well as the Internet, to 160 million homes this year. Participating stars and other notables include Celine Dion, Garth Brooks, Reba McIntyre, Sandra Bullock, Tom Hanks, Nicole Kidman, Bob Costas, and Natalie Cole.

24 Dec 2009

Stem Cell Therapy International-Histostem merger on schedule

Stem Cell Therapy International, Inc. announced that its pre-closing conditions for its merger with Histostem Co. Ltd. ("Histostem") are proceeding on schedule with an expected close of the merger in January 2010.

24 Dec 2009

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.

23 Dec 2009

Comprehensive review of cell migration

Cell migration is a highly complex process which involves several compartments of the cell, including surface receptors, signalling elements and the cytoskeleton.

23 Dec 2009

Novel discovery offers hope for patients with common brain tumor

Biomedical researchers at the University of Central Florida have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults.

23 Dec 2009

Enzyme dCK plays a profound role in normal lymphocyte development

Mice without the deoxycytidine kinase (dCK) enzyme have defects in their adaptive immune system, producing very low levels of both T and B lymphocytes, the major players involved in immune response, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center.

23 Dec 2009

NHLBI grant for identifying genetic and epigenetic causes of human congenital heart disease

Researchers at Children's Hospital Boston and Brigham and Women's Hospital have received funding from the National Heart, Lung, and Blood Institute (NHLBI) to support their search for undiscovered gene defects that cause congenital heart disease. The $4.19 million, 6-year grant is part of the Pediatric Cardiac Genomics Consortium (PCGC), which seeks to identify genetic and epigenetic causes of human congenital heart disease, and relate genetic variants present in the congenital heart disease patient population to clinical outcomes.

23 Dec 2009

Tel Aviv University's new Genome Analyzer fuels research dreams and tomorrow's cures

To identify the hemophilia mutation that affected Queen Victoria and her European relatives, scientific detectives used a cutting-edge "deep sequencing tool." Able to trace rare genetic disease mutations, the tool can turn a single laboratory into a fertile genetic research center.

22 Dec 2009

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

ProActive Capital Resources Group, a company dedicated to the discovery and creation of value in the small and micro-cap marketplace, is proud to announce client presentations at the 3rd Annual OneMedForum held in San Francisco, January 12-13, 2010. ProActive clients presenting are: Access Pharmaceuticals, ImmunoCellular Therapeutics, DataTrak International, Quantum Immunologics, with Protox Therapeutic's presentation pending.

22 Dec 2009

Cell Medica receives second grant for development of adenovirus infection therapy

Cell Medica, a clinical stage cellular therapeutics company engaged in the development and delivery of cellular immunotherapy treatment strategies for infectious disease and cancer, has announced that is has appointed four key staff to drive forwards the Company’s activities in the commercialisation of cell therapy treatments.

22 Dec 2009

Bioheart makes breakthrough in stem cell treatment for critical limb ischemia

Bioheart, Inc. offers yet another medical breakthrough with the next-level stem cell treatment for critical limb ischemia patients. The stem cells aid in promoting angiogenesis or the formation of new blood vessels and providing support for the healing of damaged blood vessels.

22 Dec 2009

Findings may help develop new antiviral drugs for influenza

Investigators at Burnham Institute for Medical Research (Burnham), Mount Sinai School of Medicine (Mount Sinai), the Salk Institute for Biological Studies (Salk) and the Genomics Institute of the Novartis Research Foundation (GNF) have identified 295 human cell factors that influenza A strains must harness to infect a cell, including the currently circulating swine-origin H1N1.

22 Dec 2009

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

NeoStem, Inc. (NYSE Amex: NBS), which is a leading provider of pre-disease adult stem cell collection, processing and long-term storage services, and holds the exclusive, worldwide license to VSEL(TM) technology that uses very small embryonic-like stem cells isolated from peripheral blood, announced today that five posters and two oral presentations at the prestigious American Society of Hematology (ASH) Annual Meeting in New Orleans in early December demonstrated the basic cellular mechanisms of very small embryonic-like stem cells.

21 Dec 2009

CSC completes a Series B financing round

California Stem Cell, Inc. (CSC), a leading stem cell company, announced that it has completed a Series B financing round with private investors. The financing will enable the company to support the advancement of its therapeutic products to human clinical trials, as well as the generation and distribution of its tools to aid in stem cell research and drug discovery.

21 Dec 2009

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

Neuralstem, Inc. today announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells has been approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA.

19 Dec 2009

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

New stem cell based technology may eliminate brain cancer

Using a novel stem cell based technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical team may eliminate a glioma -- brain cancer -- of a 36 year old Norwegian patient in a hospital in Beijing.

18 Dec 2009

Stem Cells News and Research

Further Reading

Study shows vitamin C can facilitate the generation of embryonic stem cells from adult cells

RP International benefit "The Eyes of Christmas" to be telecast to 160 million homes

Stem Cell Therapy International-Histostem merger on schedule

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

Comprehensive review of cell migration

Novel discovery offers hope for patients with common brain tumor

Enzyme dCK plays a profound role in normal lymphocyte development

NHLBI grant for identifying genetic and epigenetic causes of human congenital heart disease

Tel Aviv University's new Genome Analyzer fuels research dreams and tomorrow's cures

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

Cell Medica receives second grant for development of adenovirus infection therapy

Bioheart makes breakthrough in stem cell treatment for critical limb ischemia

Findings may help develop new antiviral drugs for influenza

Effectiveness of VSEL stem cells in regenerative medicine demonstrated at the ASH meeting

CSC completes a Series B financing round

IRB approves Neuralstem's Phase I trial to treat ALS with spinal cord stem cells

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

New stem cell based technology may eliminate brain cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo